Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).
本发明涉及H
SD17B13
抑制剂及包含所述
抑制剂的药物组合物。所述化合物和组合物可用于治疗肝病、代谢性疾病或心血管疾病,例如非
酒精性脂肪肝病(NAFLD)或非
酒精性脂肪肝炎(NASH),或药物诱导的肝损伤(DILI)。